STATUS: EDITORIAL / NOT A LAW FIRM / NOT A CLINIC
About this reading room
Source-linked summaries of the KLOW regulatory record — PubMed, FDA notices, WADA listings, and court filings.
What this site is
Legal KLOW is a regulatory reading room for the peer-reviewed literature and the public regulatory record on the KLOW research peptide blend (GHK-Cu + BPC-157 + TB-500 + KPV). It reads documents; it is not a practice built on them. No clinician and no lawyer staffs it — it offers neither medical nor legal advice, treats no one, and represents no one — and it makes, sells, compounds, and ships nothing. Its work is a plain reading of published science and public regulatory action, each claim posted to its source.
Why 'Legal KLOW'
The modifier 'legal' in the site name is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services. The regulatory record on the four KLOW components is unusually dense for a research peptide blend: an FDA Category 2 placement in September 2023, ongoing Evexias/Farmakeio litigation challenging the procedural basis of that placement, a Department of Justice prosecution of Tailor Made Compounding involving a guilty plea, a WADA S0 listing of BPC-157, separate USADA and OPSS athlete advisories, and a quietly persistent question about whether 'not a controlled substance' implies anything else at all. Reading that record requires sitting with primary sources. This site exists to make that reading easier. It does not exist to interpret the record on any specific reader's behalf.
How the site is sourced
Every quantitative claim on the site cites a primary source. Eighteen peer-reviewed studies anchor the mechanism and research-record pages. Regulatory claims cite the relevant FDA publication, WADA Prohibited List entry, USADA advisory, OPSS bulletin, or court filing. The /references page lists every primary source with DOI and PubMed/PMC links. Where the record is uncertain — for example the unpublished Pliva PL 14736 Phase 2 trial, or the limited published PK data on the TB-500 fragment — the uncertainty is stated, not papered over.
Editorial standards
The site avoids prescriptive language. It describes what the published literature reports and what the regulatory record says. It does not recommend doses, routes, sources, or use cases. Its prescription-care mentions describe provider review separately from the cited research record. It does not give legal advice on any specific situation. Where the literature is preclinical-dominated — which is the case for all four KLOW components — the preclinical character of the evidence is stated explicitly. The 2025 HSS Journal systematic review's conclusion that the human evidence base is insufficient to support clinical recommendation is the editorial benchmark for how the research is framed on this site.
What we will and will not change
Source-linked corrections are read first and acted on. If a citation is wrong, a study has been retracted, or a regulatory publication has been superseded, please send the DOI or PubMed ID of the corrected source through the contact page. Editorial framing — the choice to position the site as a regulatory reading room rather than a legal-advice or medical-advice resource — is the publisher's call and will not change in response to reader requests. The home-page prescription-care spotlight is distinct from the site's evidence record and does not alter that framing. The footer disclaimer will not change.